



# Regulation of Adaptive Immune Cells by Sirtuins

Jonathan L. Warren<sup>1</sup> and Nancie J. MacIver<sup>1,2,3\*</sup>

<sup>1</sup> Department of Pediatrics, Duke University School of Medicine, Durham, NC, United States, <sup>2</sup> Department of Immunology, Duke University School of Medicine, Durham, NC, United States, <sup>3</sup> Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC, United States

It is now well-established that the pathways that control lymphocyte metabolism and function are intimately linked, and changes in lymphocyte metabolism can influence and direct cellular function. Interestingly, a number of recent advances indicate that lymphocyte identity and metabolism is partially controlled via epigenetic regulation. Epigenetic mechanisms, such as changes in DNA methylation or histone acetylation, have been found to alter immune function and play a role in numerous chronic disease states. There are several enzymes that can mediate epigenetic changes; of particular interest are sirtuins, protein deacetylases that mediate adaptive responses to a variety of stresses (including calorie restriction and metabolic stress) and are now understood to play a significant role in immunity. This review will focus on recent advances in the understanding of how sirtuins affect the adaptive immune system. These pathways are of significant interest as therapeutic targets for the treatment of autoimmunity, cancer, and transplant tolerance.

## OPEN ACCESS

### Edited by:

Jie Chen,  
Xiamen University, China

### Reviewed by:

Terrence Deak,  
Binghamton University, United States  
Xiaoqiang Tang,  
Sichuan University, China

### \*Correspondence:

Nancie J. MacIver  
nancie.maciver@duke.edu

### Specialty section:

This article was submitted to  
Experimental Endocrinology,  
a section of the journal  
Frontiers in Endocrinology

**Received:** 02 February 2019

**Accepted:** 26 June 2019

**Published:** 11 July 2019

### Citation:

Warren JL and MacIver NJ (2019)  
Regulation of Adaptive Immune Cells  
by Sirtuins. *Front. Endocrinol.* 10:466.  
doi: 10.3389/fendo.2019.00466

**Keywords:** adaptive immunity, T cells, epigenetics, sirtuins, metabolism

## INTRODUCTION

The adaptive immune system is critical for responding to and eliminating foreign pathogens. T cells are important members of the adaptive immune system, and are generally responsible for recruiting additional inflammatory machinery to the site of infection or tumor. T cells develop within the thymus and, upon maturation, are classified broadly by their expression of either CD4 or CD8 receptor. Both CD4<sup>+</sup> and CD8<sup>+</sup> T cells exist as a number of subsets that perform unique functions within the immune milieu and exhibit unique surface receptors, produce lineage-specific cytokines, and express lineage-defining transcription factors. CD4<sup>+</sup> T effector cells (Teff) are a broad class of T cells that are further divided into unique subsets with distinct effector functions. T helper 1 (Th1) cells are necessary for combating intracellular bacteria and viruses and for producing cytokines (most notably IFN $\gamma$  and IL-2, but also TNF $\alpha$ ) to promote cellular immunity, macrophage activation, and phagocytosis (1). Th2 cells are important for responses to helminthic and other gastrointestinal parasitic infections, producing IL-4, IL-5, and IL-10, and stimulating B cell differentiation (2). Th9 cells are a relatively newly defined subset, and are known to primarily produce IL-9 and facilitate the immune response against intestinal worms (3). Th17 cells are broadly involved in inflammation as well as host response to infection, producing IL-17, IL-6, and TNF $\alpha$  to recruit additional immune cell types to the site (4). In contrast with the pro-inflammatory nature of Teff cells, regulatory T (Treg) cells are responsible for immunosuppression, preventing overactive inflammatory responses and autoimmunity (5). This subset secretes key anti-inflammatory cytokines, notably TGF $\beta$  and IL-10, and Treg differentiation is driven by the

transcription factor Foxp3. CD8<sup>+</sup> cytotoxic T cells are primarily responsible for killing infected or malignant cells through the release of cytotoxic cytokines (TNF $\alpha$ , IFN $\gamma$ ) and granules (perforin, granzymes), and by initiating apoptotic processes mediated by the caspase cascade (6). Lastly, B cells are lymphocytes derived from bone marrow and are also major players within the adaptive immune system, supporting humoral immunity upon activation by producing large quantities of antibodies (7).

The metabolic profile of each of these specialized T cell subsets is optimized to support their unique functions (8). For example, activated CD4<sup>+</sup> T<sub>H</sub> cells, including Th1, Th2, Th17, and CD8<sup>+</sup> cytotoxic T cells upregulate glucose uptake and glycolysis to promote rapid growth, proliferation, and effector function. T<sub>H</sub> cells also rely on increased glutamine uptake and metabolism to support cell growth and proliferation, although the requirement for glutamine metabolism varies among T cell subsets (9). In contrast, T<sub>reg</sub> cells rely primarily on lipid oxidation to support their suppressive activity. While considerably less is known about B cell metabolism relative to T cell metabolism, there are some similarities such that naïve B cells are relatively quiescent, but following stimulation, have increased metabolic demand, likely to support proliferation and antibody production (10). Additionally, B cell subsets tend to display unique metabolic phenotypes as a product of their environment and function (11). Thus, the pathways that control adaptive immune cell function and metabolism are intimately linked (12–14). A number of recent advances indicate that immune cell identity, function, and metabolism are controlled, at least in part, via epigenetic mechanisms.

## EPIGENETICS

While DNA sequence is the same from cell to cell within an organism, the transcription (or lack thereof) of certain genes contributes greatly to the differentiation of the myriad of cell types that are present within an organism. This variation is controlled in large part by epigenetic mechanisms that result in dynamic but heritable changes in gene expression that do not involve changes in DNA sequence (15). There are several mechanisms by which this kind of transcriptome regulation may occur. One example of these mechanisms is DNA methylation, the addition of a methyl group to cytosine residues within DNA by various DNA methyltransferases typically in regions rich in cytosine-guanine dinucleotides. Generally, DNA methylation can act to either inhibit gene transcription (if methylation occurs within a promoter region) or promote transcription (if methylation occurs within the gene body) (16). Another mechanism of epigenetic regulation occurs via non-coding RNA. These single-stranded RNA fragments seek out complementary sites within the mRNA of target genes and degrade RNA, ultimately preventing translation (17). Lastly, the modification of histones is a highly prevalent mechanism of epigenetic control and contributes to genetic regulation by altering the physical structure of chromatin to improve or impair the accessibility


of DNA to various transcription factors and transcription machinery. Histones form the backbone of the nucleosome, providing structure and stability. In contrast with the stability of DNA methylation, histone modifications can be more fluid over acute periods of time (18). Deacetylated histones form a densely packed chromatin structure, known as heterochromatin, physically preventing transcription. Histone acetylation maintains a more loose and fluid chromatin structure. Other common histone modifications can occur by methylation, phosphorylation, and deamination. Moreover, all of these mechanisms likely work synergistically to regulate the epigenome (19).

## SIRTUINS

Among the four defined classes of histone deacetylases, sirtuins (class III) are a unique family of highly conserved, NAD<sup>+</sup>-dependent protein deacetylases with important implications on the epigenome. In addition to their deacetylase activity, sirtuins display some additional enzymatic function on other substrates, including ADP-ribosyltransferase and desuccinylase activity (20, 21). Mammalian sirtuins are orthologs of the silent information regulatory 2 (Sir2) protein, which was first identified in yeast as a significant contributor to the life-span extending effects of calorie restriction (22). These effects were further observed in *C. elegans* and *Drosophila* (23), suggesting that this pathway is conserved across species. Given the NAD<sup>+</sup>-dependent activity of sirtuins, they are activated in periods of catabolism and low nutrient availability, and were thus thought to be a novel target for mimicking the life-span extending effects of calorie restriction in humans.

Mammals ubiquitously express seven sirtuins (SIRT1–SIRT7) with different subcellular locations and functions. Sirtuins are currently gaining widespread attention in the context of a number of disease states associated with inflammation, including autoimmunity (24), cardiometabolic diseases (25), and cancers (26). Further, the mammalian sirtuins have been found to mediate cellular metabolism and adaptive responses to a variety of stresses, including calorie restriction and other metabolic stress (27). Given the relationship between nutrient availability and the function of the adaptive immune system (28), sirtuins are currently of great interest as mediators of tumor proliferation, autoimmunity, and the ability of an organism to respond to foreign pathogens.

The idea that sirtuins might be involved in immunity was posited over a decade ago (23), following the early finding that SIRT1 can regulate NF- $\kappa$ B (29), a transcription factor well-known to regulate inflammation and immune cell proliferation (30). Indeed, further study has begun to elucidate the link between this family of proteins and immune cell function. While each of the sirtuins has since been broadly studied, the most intense attention has been given to SIRT1 (primarily localized to the nucleus) and SIRT3 (primarily in mitochondria) with respect to adaptive immune cells, and will thus be the focus of this review (**Figure 1**). Further, considerations for the use of sirtuin-modifying drugs to manipulate immune activity are explored.



## EFFECTOR CD4<sup>+</sup> T CELLS

Activation of T cells occurs seconds after stimulation of the T cell antigen receptor (TCR) by a ligand, along with co-stimulatory signals, which initiate a number of signaling pathways that promote differentiation and growth. This activation is supported by a transition from a relatively quiescent oxidative metabolism to an intense glycolytic metabolic signature to support proliferation and cytokine production (12). This metabolic switch is likely driven, at least in part, by sirtuin activity, however there presently appears to be a number of incongruous effects reported across the various CD4<sup>+</sup> T cell subsets.

SIRT1 appears to play a significant role in the regulation of Teff cell activation (31, 32). Early studies into the function of SIRT1 on Teff cells indicated that SIRT1 inhibits the immune response by acting as an antagonist against transcription factors that support IL-2 production (32) and thereby decreasing Th1 cell activation. This relationship may contribute in part to the link between fasting/calorie restriction and poor immune performance (28), given that SIRT1 is generally activated in response to fasting (33). The direct role of sirtuins within adaptive immune cells has also begun to be studied using knockout (KO) animal models. T cells from a SIRT1 KO mouse model are more proliferative, produce more IL-2 both *in vitro* and *in vivo*, and these mice are more susceptible to experimental autoimmune encephalomyelitis (EAE), indicating a more inflammatory immune phenotype (32). Studies in SIRT1 KO animals also found that T cells without SIRT1 can be activated solely via the T cell receptor (TCR), without co-stimulation by CD28, suggesting a hypersensitivity to activation signals when SIRT1 is not present (32). Follow-up studies indicated that IL-2 is involved in a feedback response to reduce further SIRT1 gene transcription and allow for proliferation in response to the activation cascade (34). Hyper-responsive Teff cells can contribute to an environment prone to autoimmune disease. In fact, earlier studies in SIRT1-null mice detailed the development of a mild autoimmune condition that resembled systemic lupus erythematosus, characterized by deposition of immune complexes within liver and kidneys, with some mice going on to spontaneously develop a diabetes insipidus-like autoimmune

disorder after 2 years of age, altogether suggesting a preventative role of SIRT1 in autoimmunity (35).

SIRT1 also inhibits Bcl-2 Associated Transcription Factor 1 (Bclaf1) (36). Bclaf1 was originally identified as a promoter of apoptosis (37); however, subsequent studies revealed further reaching effects of Bclaf1 on T cell development, activation, and proliferation (38), perhaps by promoting hypoxia-inducible factor 1- $\alpha$  (HIF-1 $\alpha$ ) transcription (39). SIRT1-mediated inhibition of Bclaf1 is thought to occur by the binding of SIRT1 to the promoter region of Bclaf1 after stimulation of the TCR, suppressing acetylation of the histone 3 lysine 56 residue (H3K56) (36). When SIRT1 was knocked out of T cells, there was greater expression of the gene coding for Bclaf1, and specific knockdown of Bclaf was able to suppress the increase in IL-2 production and proliferation seen in SIRT1 KO mice (36).

SIRT1 inhibition can also depress the adaptive response and differentiation of Th2 cells. Pharmacological SIRT1 inhibition contributed to decreased allergic inflammation in BALB/c mice exposed to ovalbumin via aerosol (40). In addition, mice that exhibit KO of a transcriptional activator essential for Th2 differentiation (B-cell lymphoma/leukemia 11B; Bcl11b) have been found to be protected against EAE (41). Bcl11b is a transcriptional repressor and likely functions by recruiting SIRT1 for histone deacetylase activity (42). Although T helper 9 (Th9) cells exhibit a number of similarities to Th2 cells, SIRT1 inhibition has been found to promote Th9 cell differentiation and IL-9 production by these cells (43).

The implications of SIRT1 on Th17 cells have been more equivocal. Pharmacological induction of SIRT1 using resveratrol, low dose metformin, or the inhibitor SRT1720 has been shown to impair Th17 cell differentiation with decreased expression of IL-17 and ROR $\gamma$ t, in a STAT3-dependent manner (44). The same study further describes anti-tumor effects of metformin by its action in reducing Th17 differentiation and STAT3 acetylation. In a separate study, *in vivo* activation of SIRT1 through treatment with NAD<sup>+</sup> contributed to a delayed onset of EAE. This protection was hypothesized to be conferred by enhanced SIRT1 expression within the spinal cord of mice exposed to the EAE stimulus, which may suppress inflammatory responses by Th1 and Th17 cells (45). However, others have shown that SIRT1 is necessary for the production of pro-inflammatory Th17 cells

through the deacetylation of transcription factor ROR $\gamma$ t, which suggests that SIRT1 inhibitors could confer protection against autoimmunity (46). Clearly, more studies are needed to dissect out the role of SIRT1 in Th17 cell differentiation, proliferation, and cytokine response.

SIRT3 is a mitochondrial sirtuin that supports the structure, function, and biogenesis of the mitochondria (47). SIRT3 is elevated in fasting and calorie restriction in liver, muscle, and brown adipose tissue, and is known to modify cellular metabolism in those tissues (48, 49). In a model of experimental allogeneic bone marrow transplantation, total T cells from donor animals that exhibit a whole-body SIRT3 KO were less likely to promote graft-vs.-host disease relative to T cells from control mice, but did not affect the graft-vs.-tumor effect, suggesting that targeted inhibition of SIRT3 in allogeneic T cells can improve outcomes after transplant (50). Further, while SIRT3 KO did not affect the composition of peripheral naïve T cell subsets, it was determined that SIRT3 KO Teff cells were less proliferative and produced less reactive oxygen species (ROS) in response to non-specific TCR stimulation (50). However, a SIRT3 KO mouse model did not affect the development of immune cells or immune responses to various endotoxins (51), suggesting SIRT3 may play a limited role in Teff cell function.

Little is known about the role of the other sirtuins on Teff cell development and function. SIRT6 may be a negative regulator of glycolytic activity, notably through the inhibition of glucose transporter 1 (GLUT1) and the transcriptional regulator HIF-1 $\alpha$  (52), suggesting a potential role for SIRT6 in downregulating Teff cell activation. HIF-1 $\alpha$  is a transcriptional regulator of glycolysis and is known to regulate the production of a number of cytokines (53) and enhance Th17 cell differentiation (54). Relatively little work has been done on SIRT2 in adaptive immunity. However, SIRT2 has been identified as a potential suppressor of colitis through its deacetylase activity on NF- $\kappa$ B within bone marrow-derived macrophages in a mouse model (55). Further, this study observed a greater proportion of activated (CD4<sup>+</sup>CD69<sup>+</sup>) T cell populations at the mesenteric lymph nodes of SIRT2 KO mice in response to DSS-induced colitis, indicative of enhanced inflammatory action (55), and ascribing a role for SIRT2, similar to SIRT1, in limiting CD4<sup>+</sup> Teff cell inflammation.

## REGULATORY CD4<sup>+</sup> T CELLS

SIRT1 has been found to reduce the activity of Foxp3, contributing to an overall more inflammatory immune phenotype (46). Further, inhibiting SIRT1 can promote greater Treg suppressive activity (56, 57). While the regulation of Treg metabolism by sirtuins has not been widely studied, Treg function has been shown to be regulated in part by sirtuin activity. In addition, Foxp3 itself has been found to be a regulator of epigenetic activity to support the Treg phenotype, and is regulated in part by the deacetylase activity of SIRT1 (56). A previous review has outlined the role of demethylation and histone modifications that occur in order to promote and stabilize the expression of Foxp3 during Treg cell development (58). Briefly, three conserved non-coding sequences are primary

targets for epigenetic mechanisms that regulate Foxp3 expression in response to external environmental stimulus.

Given the localization of SIRT3 to the mitochondria and its role in oxidative metabolism and mitochondrial function, it is not surprising that the loss of SIRT3 in Treg cells has been shown to impair their suppressive activity (59). Indeed, deletion of histone deacetylase 9 was found to be sufficient to increase Treg suppressive activity, by increasing the expression of SIRT3. Further, Treg cells from SIRT3 KO mice had impaired suppressive function both in an *in vitro* suppression assay and an *in vivo* cardiac allograft model, likely due to the role of SIRT3 in promoting oxidative metabolism (59).

## CD8<sup>+</sup> T CELLS

Activation and differentiation of CD8<sup>+</sup> T cells leads to markedly variable chromatin accessibility (60), which is likely critical to facilitate the transition between naïve, effector, and memory CD8<sup>+</sup> T cells. SIRT1 appears to play a crucial role in CD8<sup>+</sup> T cell differentiation. Basic leucine zipper ATF-like transcription factor (BATF) has been shown to inhibit the expression of SIRT1, contributing to increased histone acetylation, particularly at the T-bet locus (61). This has been shown to affect CD8<sup>+</sup> T cell differentiation and activity, as CD8<sup>+</sup> T cells from BATF KO animals exhibited lower ATP production and lower mRNA expression of perforin and IFN $\gamma$  (61). SIRT3 is also involved in CD8<sup>+</sup> T cell function. Toubai et al. found that SIRT3-null activated CD8<sup>+</sup> T cells produced less ROS upon activation (50). This impairment in ROS production may lead to impairments in sulfenylation, a process known to play a role in the regulation of histone deacetylases (62). Further SIRT3-null donor cells were able to attenuate graft-vs.-host disease within the gastrointestinal tract and the authors hypothesize this may be due, in part, to decreased CD8<sup>+</sup> T cell trafficking to site (50).

## MEMORY T CELLS

Following the primary immune response, a portion of T cells (CD4<sup>+</sup> and CD8<sup>+</sup>) can become memory cells that remain ready to respond rapidly in the event that they re-encounter their antigen. These cells are relatively long-lived and therefore exhibit a relatively quiescent oxidative metabolism similar to that of a naïve immune cell until they are re-activated. Little is known about the role of sirtuins in mediating the generation or longevity of memory T cells; however, given the role of sirtuins in promoting oxidative metabolism, this is a potentially interesting area for further study. Though not specific to memory T cells, SIRT1 has distinct effects on PGC-1 $\alpha$  and PGC-1 $\beta$ , both proteins with roles in facilitating mitochondrial biogenesis and oxidative metabolism. Thus, the return to a more oxidative metabolism in memory cells may be mediated in part by SIRT1, given the role of SIRT1-mediated deacetylation on transcription of PGC-1 $\alpha$  and PGC-1 $\beta$  (63, 64). In support of this hypothesis, SIRT1 expression has been shown to be decreased in terminally differentiated CD8<sup>+</sup>CD28<sup>-</sup> memory T cells, driving the downregulation of forkhead box protein O1 (FoxO1), a transcription factor that mediates T cell homing and differentiation (65). Further,

these authors demonstrate that these SIRT1-low CD8<sup>+</sup>CD28<sup>-</sup> memory cells have an enhanced glycolytic capacity in the resting state, which can support effector function upon reactivation.

## B CELLS

Naïve B cells exhibit a relatively inert epigenetic status with high levels of DNA methylation and histone deacetylation. However, upon activation and maturation toward a germinal center B cell phenotype, B cells exhibit dramatic shifts in methylation status and become hypomethylated with increased histone acetylation and expression of various miRNAs (66, 67). Thus far, the limited literature on sirtuin activity in B cells indicates sirtuins support B cell viability, proliferation, and function. SIRT1 overexpression by viral transfection in BaF3 B cells (a murine B cell line) has been shown to support enhanced viability (mediated in part by a decrease in p53) and increased cytokine production (68). A short, non-coding microRNA, miR-132, is increased in B cells of patients with multiple sclerosis (MS) concurrent with a reduced expression of SIRT1 (69). SIRT3 also has been found to be a tumor suppressor in the context of B cell malignancies, as a number of malignant B cell lines display decreased SIRT3 protein expression and higher ROS levels, and overexpression of SIRT3 in these lines decreased proliferative activity (70). SIRT4 has also been shown to act as a tumor suppressor by inhibiting glutamine metabolism, which is necessary to conserve resources for repairing DNA damage (71). Further, SIRT4 overexpression can inhibit proliferation of Burkitt lymphoma cells, a model of B cell lymphoma (72). Inhibition of SIRT1 and SIRT2 increased apoptotic activity and ROS production in cells from patients with B cell chronic lymphocytic leukemia (73). While not specific to sirtuins, histone deacetylase inhibitors have been shown to be effective in preventing B cell malignancies (74).

## MODULATING SIRTUIN ACTIVITY TO ALTER IMMUNE OUTCOMES *IN VIVO*

A number of novel drugs with sirtuin modulatory activity have been studied in the context of immune function. However, it will be critical to determine whether to induce or inhibit sirtuin activity and, further, how to target specific sirtuins (perhaps even within a particular lymphocyte subset), in order to reach desired immune outcomes. For instance, promoting SIRT3 activity in Treg cells to improve suppressive capabilities and temper inflammation could be a novel means to treat autoimmunity. On the other hand, SIRT1 generally inhibits T<sub>H</sub>17 inflammation, suggesting that activators of SIRT1 could be useful for the treatment of autoimmune disease; however, the effects of SIRT1 on T cells vary by subset and are context-dependent. As sirtuins are proteins with functions in a wide array of cell types, targeting specific sirtuins in specific tissues (and immune cell subsets) will remain an immense challenge.

Despite the challenges with tissue-specificity, drugs to modify sirtuin activity have been studied in cell culture and animal models. Inhibition of SIRT1 *in vivo* (using a SIRT1-specific inhibitor, EX-527) increased complications of sepsis at 12 h despite conferring dramatic protection at 24 h (75). EX-527

and sirtinol (another commonly studied sirtuin inhibitor with specificity against SIRT1 and SIRT2) also have been found to reduce platelet count (76). Metformin, classically prescribed as a medication for the management of type 2 diabetes, has been well-documented to have anticancer effects (77); however, the precise mechanism of action is largely unknown, though there is speculation that these effects may be due to the stimulatory effect of metformin on sirtuins. SIRT1 activation by metformin has been shown to decrease Th17 cell populations promoting a less inflammatory environment (44). SIRT1 knockdown has also been shown to promote apoptotic processes in leukemia cells (78), suggesting the exact mechanisms for sirtuin modulation in cancers is still being determined.

Resveratrol, a polyphenol compound with anti-inflammatory properties, is a compound with sirtuin modifying effects that is currently of intense interest within both the scientific and lay communities. Resveratrol increases SIRT1 activity and impedes acetylation of c-Jun, thereby limiting T cell activation (79). Further, resveratrol has been shown to improve outcomes in two well-characterized murine models of autoimmunity: EAE (80) and colitis (81). Additionally, resveratrol confers protection against a murine model of rheumatoid arthritis, by inhibiting Th17 expansion and IL-17 production, as well as autoantibody production from B cells (82). Resveratrol has also been shown to increase the ratio of CD4<sup>+</sup> to CD8<sup>+</sup> T cells and increase total Treg cells in the context of diet-induced obesity in mice while also conferring benefits on glucose homeostasis by activating phosphoinositide 3-kinase (PI3K) signaling pathways (83). Dosages necessary to produce these effects in humans are likely impossible to obtain exclusively through diet, but could realistically be obtained through supplementation.

The role of sirtuins in promoting organ transplant tolerance is also an area of intense investigation. While advances have been made in long-term survival following transplantation, current immunosuppressive therapies are known to promote infections and cancer. There is speculation that SIRT1 inhibitors may enhance the function of Treg cells to support immune suppression and allograft tolerance (84). Additionally, SIRT1 inhibitors may also confer prolonged allograft survival through the suppression of Th17 activity, as evidenced by decreased IL-17A (85); however, these results are in direct opposition to the SIRT1-activating and anti-tumor properties of metformin described above (44), and further studies are needed.

## CONCLUDING REMARKS

The wide-ranging effects of sirtuins and the availability of a number of sirtuin-modifying compounds provide a significant opportunity for future study to improve immune cell phenotypes. However, there are significant challenges ahead in developing drugs with targeted tissue-specific effects given the ubiquity of these mechanisms within the body. The development of tissue-specific and sirtuin-specific therapies remains an intriguing possibility to treat the myriad of autoimmune diseases, cancers, and other chronic diseases associated with inflammation that are now understood to be regulated by some degree of protein acetylation.

## AUTHOR CONTRIBUTIONS

All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.

## REFERENCES

- Romagnani S. T-cell subsets (Th1 versus Th2). *Ann Allergy Asthma Immunol.* (2000) 85:9–18. doi: 10.1016/S1081-1206(10)62426-X
- Smith KM, Pottage L, Thomas ER, Leishman AJ, Doig TN, Xu D, et al. Th1 and Th2 CD4+ T cells provide help for B cell clonal expansion and antibody synthesis in a similar manner *in vivo*. *J Immunol.* (2000) 165:3136–44. doi: 10.4049/jimmunol.165.6.3136
- Vyas SP, Goswami R. A Decade of Th9 Cells: Role of Th9 cells in inflammatory bowel disease. *Front Immunol.* (2018) 9:1139. doi: 10.3389/fimmu.2018.01139
- Tesmer LA, Lundy SK, Sarkar S, Fox DA. Th17 cells in human disease. *Immunol Rev.* (2008) 223:87–113. doi: 10.1111/j.1600-065X.2008.00628.x
- Schmidt A, Oberle N, Krammer PH. Molecular mechanisms of treg-mediated T cell suppression. *Front Immunol.* (2012) 3:51. doi: 10.3389/fimmu.2012.00051
- Alam A, Cohen LY, Aouad S, Sékaly RP. Early activation of caspases during T lymphocyte stimulation results in selective substrate cleavage in nonapoptotic cells. *J Exp Med.* (1999) 190:1879–90. doi: 10.1084/jem.190.12.1879
- Hoffman W, Lakkis FG, Chalasani G. B cells, antibodies, and more. *Clin J Am Soc Nephrol.* (2016) 11:137–54. doi: 10.2215/CJN.09430915
- Michalek RD, Gerriets VA, Jacobs SR, Macintyre AN, MacIver NJ, Mason EF, et al. Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets. *J Immunol.* (2011) 186:3299–303. doi: 10.4049/jimmunol.1003613
- Johnson MO, Wolf MM, Madden MZ, Andrejeva G, Sugiura A, Contreras DC, et al. Distinct regulation of Th17 and Th1 cell differentiation by glutaminase-dependent metabolism. *Cell.* (2018) 175:1780–95.e19. doi: 10.1016/j.cell.2018.10.001
- Caro-Maldonado A, Wang R, Nichols AG, Kuraoka M, Milasta S, Sun LD, et al. Metabolic reprogramming is required for antibody production that is suppressed in anergic but exaggerated in chronically BAFF-exposed B cells. *J Immunol.* (2014) 192:3626–36. doi: 10.4049/jimmunol.1302062
- Clarke AJ, Riffelmacher T, Braas D, Cornall RJ, Simon AK. B1a B cells require autophagy for metabolic homeostasis and self-renewal. *J Exp Med.* (2018) 215:399–413. doi: 10.1084/jem.20170771
- MacIver NJ, Michalek RD, Rathmell JC. Metabolic regulation of T lymphocytes. *Annu Rev Immunol.* (2013) 31:259–83. doi: 10.1146/annurev-immunol-032712-095956
- Buck MD, O'Sullivan D, Pearce EL. T cell metabolism drives immunity. *J Exp Med.* (2015) 212:1345–60. doi: 10.1084/jem.20151159
- Buck MD, Sowell RT, Kaech SM, Pearce EL. Metabolic instruction of immunity. *Cell.* (2017) 169:570–86. doi: 10.1016/j.cell.2017.04.004
- Xu W, Wang F, Yu Z, Xin F. Epigenetics and cellular metabolism. *Gene Epigenet.* (2016) 8:43–51. doi: 10.4137/GEG.S32160
- Maunakea AK, Chepelev I, Cui K, Zhao K. Intragenic DNA methylation modulates alternative splicing by recruiting MeCP2 to promote exon recognition. *Cell Res.* (2013) 23:1256–69. doi: 10.1038/cr.2013.110
- Frías-Lasserre D, Villagra CA. The importance of ncRNAs as epigenetic mechanisms in phenotypic variation and organic evolution. *Front Microbiol.* (2017) 8:2483. doi: 10.3389/fmicb.2017.02483
- Hansen JC, Nyborg JK, Luger K, Stargell LA. Histone chaperones, histone acetylation, and the fluidity of the chromogenome. *J Cell Physiol.* (2010) 224:289–99. doi: 10.1002/jcp.22150
- Rose NR, Klose RJ. Understanding the relationship between DNA methylation and histone lysine methylation. *Biochim Biophys Acta.* (2014) 1839:1362–72. doi: 10.1016/j.bbaggm.2014.02.007
- Hawse WF, Wolberger C. Structure-based mechanism of ADP-ribosylation by sirtuins. *J Biol Chem.* (2009) 284:33654–61. doi: 10.1074/jbc.M109.024521
- Du J, Zhou Y, Su X, Yu JJ, Khan S, Jiang H, et al. Sirt5 is a NAD-dependent protein lysine demalonylase and desuccinylase. *Science.* (2011) 334:806–9. doi: 10.1126/science.1207861
- Guarente L. Diverse and dynamic functions of the Sir silencing complex. *Nat Genetics.* (1999) 23:281–5. doi: 10.1038/15458
- Guarente L. Sirtuins in aging and disease. *Cold Spring Harbor Symp Quant Biol.* (2007) 72:483–8. doi: 10.1101/sqb.2007.72.024
- Kong S, McBurney MW, Fang D. Sirtuin 1 in immune regulation and autoimmunity. *Immunol Cell Biol.* (2012) 90:6–13. doi: 10.1038/icb.2011.102
- Tang X, Chen XF, Chen HZ, Liu DP. Mitochondrial Sirtuins in cardiometabolic diseases. *Clin Sci.* (2017) 131:2063–78. doi: 10.1042/CS20160685
- Jeong SM, Haigis MC. Sirtuins in cancer: a balancing act between genome stability and metabolism. *Mol Cells.* (2015) 38:750–8. doi: 10.14348/molcells.2015.0167
- Haigis MC, Guarente LP. Mammalian sirtuins—emerging roles in physiology, aging, and calorie restriction. *Genes Dev.* (2006) 20:2913–21. doi: 10.1101/gad.1467506
- Alwarawrah Y, Kiernan K, MacIver NJ. Changes in nutritional status impact immune cell metabolism and function. *Front Immunol.* (2018) 9:1055. doi: 10.3389/fimmu.2018.01055
- Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, Frye RA, et al. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. *EMBO J.* (2004) 23:2369–80. doi: 10.1038/sj.emboj.7600244
- Hayden MS, West AP, Ghosh S. NF-kappaB and the immune response. *Oncogene.* (2006) 25:6758–80. doi: 10.1038/sj.onc.1209943
- Gao X, Xu YX, Janakiraman N, Chapman RA, Gautam SC. Immunomodulatory activity of resveratrol: suppression of lymphocyte proliferation, development of cell-mediated cytotoxicity, and cytokine production. *Biochem Pharmacol.* (2001) 62:1299–308. doi: 10.1016/s0006-2952(01)00775-4
- Zhang J, Lee SM, Shannon S, Gao B, Chen W, Chen A, et al. The type III histone deacetylase Sirt1 is essential for maintenance of T cell tolerance in mice. *J Clin Invest.* (2009) 119:3048–58. doi: 10.1172/JCI38902
- Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, Puigserver P. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. *Nature.* (2005) 434:113–8. doi: 10.1038/nature03354
- Gao B, Kong Q, Kemp K, Zhao YS, Fang D. Analysis of sirtuin 1 expression reveals a molecular explanation of IL-2-mediated reversal of T-cell tolerance. *Proc Natl Acad Sci USA.* (2012) 109:899–904. doi: 10.1073/pnas.1118462109
- Sequeira J, Boily G, Bazinet S, Saliba S, He X, Jardine K, et al. sirt1-null mice develop an autoimmune-like condition. *Exp Cell Res.* (2008) 314:3069–74. doi: 10.1016/j.yexcr.2008.07.011
- Kong S, Kim SJ, Sandal B, Lee SM, Gao B, Zhang DD, et al. The type III histone deacetylase Sirt1 protein suppresses p300-mediated histone H3 lysine 56 acetylation at Bclaf1 promoter to inhibit T cell activation. *J Biol Chem.* (2011) 286:16967–75. doi: 10.1074/jbc.M111.218206
- Haraguchi T, Holaska JM, Yamane M, Koujin T, Hashiguchi N, Mori C, et al. Emerin binding to Btf, a death-promoting transcriptional repressor, is disrupted by a missense mutation that causes Emery-Dreifuss muscular dystrophy. *Eur J Biochem.* (2004) 271:1035–45. doi: 10.1111/j.1432-1033.2004.04007.x
- McPherson JP, Sarras H, Lemmers B, Tamblin L, Migon E, Matsiyak-Zablocki E, et al. Essential role for Bclaf1 in lung development and immune system function. *Cell Death Differ.* (2009) 16:331–9. doi: 10.1038/cdd.2008.167

## FUNDING

This work was supported by the National Institutes of Health (R01-DK106090) and the Derfner Foundation.

39. Wen Y, Zhou X, Lu M, He M, Tian Y, Liu L, et al. Bclaf1 promotes angiogenesis by regulating HIF-1 $\alpha$  transcription in hepatocellular carcinoma. *Oncogene*. (2018) 38:1845–59. doi: 10.1038/s41388-018-0552-1
40. Legutko A, Marichal T, Fievez L, Bedoret D, Mayer A, de Vries H, et al. Sirtuin 1 promotes Th2 responses and airway allergy by repressing peroxisome proliferator-activated receptor-gamma activity in dendritic cells. *J Immunol*. (2011) 187:4517–29. doi: 10.4049/jimmunol.1101493
41. Lorentsen KJ, Cho JJ, Luo X, Zuniga AN, Urban JF Jr, Zhou L, et al. Bcl11b is essential for licensing Th2 differentiation during helminth infection and allergic asthma. *Nat Commun*. (2018) 9:1679. doi: 10.1038/s41467-018-04111-0
42. Senawong T, Peterson VJ, Avram D, Shepherd DM, Frye RA, Minucci S, et al. Involvement of the histone deacetylase SIRT1 in chicken ovalbumin upstream promoter transcription factor (COUP-TF)-interacting protein 2-mediated transcriptional repression. *J Biol Chem*. (2003) 278:43041–50. doi: 10.1074/jbc.M307477200
43. Wang Y, Bi Y, Chen X, Li C, Li Y, Zhang Z, et al. Histone deacetylase SIRT1 negatively regulates the differentiation of interleukin-9-producing CD4(+) T cells. *Immunity*. (2016) 44:1337–49. doi: 10.1016/j.immuni.2016.05.009
44. Limagne E, Thibaudin M, Euvrard R, Berger H, Chalons P, Vegan F, et al. Sirtuin-1 activation controls tumor growth by impeding Th17 differentiation via STAT3 deacetylation. *Cell Reports*. (2017) 19:746–59. doi: 10.1016/j.celrep.2017.04.004
45. Wang J, Zhao C, Kong P, Sun H, Sun Z, Bian G, et al. Treatment with NAD(+) inhibited experimental autoimmune encephalomyelitis by activating AMPK/SIRT1 signaling pathway and modulating Th1/Th17 immune responses in mice. *Int Immunopharmacol*. (2016) 39:287–94. doi: 10.1016/j.intimp.2016.07.036
46. Lim HW, Kang SG, Ryu JK, Schilling B, Fei M, Lee IS, et al. SIRT1 deacetylates ROR $\gamma$  and enhances Th17 cell generation. *J Exp Med*. (2015) 212:607–17. doi: 10.1084/jem.20132378
47. Giralt A, Villarroya F. SIRT3, a pivotal actor in mitochondrial functions: metabolism, cell death and aging. *Biochem J*. (2012) 444:1–10. doi: 10.1042/BJ20120030
48. Hirschev MD, Shimazu T, Goetzman E, Jing E, Schwer B, Lombard DB, et al. SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. *Nature*. (2010) 464:121–5. doi: 10.1038/nature08778
49. Newman JC, He W, Verdin E. Mitochondrial protein acylation and intermediary metabolism: regulation by sirtuins and implications for metabolic disease. *J Biol Chem*. (2012) 287:42436–43. doi: 10.1074/jbc.R112.404863
50. Toubai T, Tamaki H, Peltier DC, Rossi C, Oravec-Wilson K, Liu C, et al. Mitochondrial deacetylase SIRT3 plays an important role in donor T cell responses after experimental allogeneic hematopoietic transplantation. *J Immunol*. (2018) 201:3443–55. doi: 10.4049/jimmunol.1800148
51. Ciarlo E, Heinonen T, Lugin J, Acha-Orbea H, Le Roy D, Auwerx J, et al. Sirtuin 3 deficiency does not alter host defenses against bacterial and fungal infections. *Sci Reports*. (2017) 7:3853. doi: 10.1038/s41598-017-04263-x
52. Zhong L, D'Urso A, Toiber D, Sebastian C, Henry RE, Vadysirisack DD, et al. The histone deacetylase Sirt6 regulates glucose homeostasis via Hif1 $\alpha$ . *Cell*. (2010) 140:280–93. doi: 10.1016/j.cell.2009.12.041
53. Krzywinska E, Stockmann C. Hypoxia, metabolism and immune cell function. *Biomedicines*. (2018) 6:56. doi: 10.3390/biomedicines6020056
54. Dang EV, Barbi J, Yang HY, Jinasena D, Yu H, Zheng Y, et al. Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. *Cell*. (2011) 146:772–84. doi: 10.1016/j.cell.2011.07.033
55. Lo Sasso G, Menzies KJ, Mottis A, Piersigilli A, Perino A, Yamamoto H, et al. SIRT2 deficiency modulates macrophage polarization and susceptibility to experimental colitis. *PLoS ONE*. (2014) 9:e103573. doi: 10.1371/journal.pone.0103573
56. van Loosdregt J, Vercoulen Y, Guichelaar T, Gent YY, Beekman JM, van Beekum O, et al. Regulation of Treg functionality by acetylation-mediated Foxp3 protein stabilization. *Blood*. (2010) 115:965–74. doi: 10.1182/blood-2009-02-207118
57. Kwon HS, Lim HW, Wu J, Schnolzer M, Verdin E, Ott M. Three novel acetylation sites in the Foxp3 transcription factor regulate the suppressive activity of regulatory T cells. *J Immunol*. (2012) 188:2712–21. doi: 10.4049/jimmunol.1100903
58. Huehn J, Beyer M. Epigenetic and transcriptional control of Foxp3+ regulatory T cells. *Semin Immunol*. (2015) 27:10–8. doi: 10.1016/j.smim.2015.02.002
59. Beier UH, Angelin A, Akimova T, Wang L, Liu Y, Xiao H, et al. Essential role of mitochondrial energy metabolism in Foxp3(+) T-regulatory cell function and allograft survival. *FASEB J*. (2015) 29:2315–26. doi: 10.1096/fj.14-268409
60. Scott-Browne JP, López-Moyado IE, Trifari S, Wong V, Chavez L, Rao A, et al. Dynamic changes in chromatin accessibility occur in CD8(+) T cells responding to viral infection. *Immunity*. (2016) 45:1327–40. doi: 10.1016/j.immuni.2016.10.028
61. Kuroda S, Yamazaki M, Abe M, Sakimura K, Takayanagi H, Iwai Y. Basic leucine zipper transcription factor, ATF-like (BATF) regulates epigenetically and energetically effector CD8 T-cell differentiation via Sirt1 expression. *Proc Natl Acad Sci USA*. (2011) 108:14885–9. doi: 10.1073/pnas.1105133108
62. Franchina DG, Dostert C, Brenner D. Reactive oxygen species: involvement in T Cell signaling and metabolism. *Trends Immunol*. (2018) 39:489–502. doi: 10.1016/j.it.2018.01.005
63. Cantó C, Auwerx J. PGC-1 $\alpha$ , SIRT1 and AMPK, an energy sensing network that controls energy expenditure. *Curr Opin Lipidol*. (2009) 20:98–105. doi: 10.1097/MOL.0b013e328328d0a4
64. Kelly TJ, Lerin C, Haas W, Gygi SP, Puigserver P. GCN5-mediated transcriptional control of the metabolic coactivator PGC-1 $\beta$  through lysine acetylation. *J Biol Chem*. (2009) 284:19945–52. doi: 10.1074/jbc.M109.015164
65. Jeng MY, Hull PA, Fei M, Kwon HS, Tsou CL, Kasler H, et al. Metabolic reprogramming of human CD8(+) memory T cells through loss of SIRT1. *J Exp Med*. (2018) 215:51–62. doi: 10.1084/jem.20161066
66. Wu H, Deng Y, Feng Y, Long D, Ma K, Wang X, et al. Epigenetic regulation in B-cell maturation and its dysregulation in autoimmunity. *Cell Mol Immunol*. (2018) 15:676–84. doi: 10.1038/cmi.2017.133
67. Shklovich R, Cerchiotti L, Tsikitas L, Kormaksson M, De S, Figueroa ME, et al. DNA methyltransferase 1 and DNA methylation patterning contribute to germinal center B-cell differentiation. *Blood*. (2011) 118:3559–69. doi: 10.1182/blood-2011-06-357996
68. Wang Q, Yan C, Xin M, Han L, Zhang Y, Sun M. Sirtuin 1 (Sirt1) overexpression in BaF3 cells contributes to cell proliferation promotion, apoptosis resistance and pro-inflammatory cytokine production. *Med Sci Monit*. (2017) 23:1477–82. doi: 10.12659/MSM.900754
69. Miyazaki Y, Li R, Rezk A, Misirliyan H, Moore C, Farooqi N, et al. A novel microRNA-132-sirtuin-1 axis underlies aberrant B-cell cytokine regulation in patients with relapsing-remitting multiple sclerosis [corrected]. *PLoS ONE*. (2014) 9:e105421. doi: 10.1371/journal.pone.0105421
70. Yu W, Denu RA, Krautkramer KA, Grindle KM, Yang DT, Asimakopoulos F, et al. Loss of SIRT3 provides growth advantage for B cell malignancies. *J Biol Chem*. (2016) 291:3268–79. doi: 10.1074/jbc.M115.702076
71. Jeong SM, Xiao C, Finley LW, Lahusen T, Souza AL, Pierce K, et al. SIRT4 has tumor-suppressive activity and regulates the cellular metabolic response to DNA damage by inhibiting mitochondrial glutamine metabolism. *Cancer Cell*. (2013) 23:450–63. doi: 10.1016/j.ccr.2013.02.024
72. Jeong SM, Lee A, Lee J, Haigis MC. SIRT4 protein suppresses tumor formation in genetic models of Myc-induced B cell lymphoma. *J Biol Chem*. (2014) 289:4135–44. doi: 10.1074/jbc.M113.525949
73. Bhalla S, Gordon LI. Functional characterization of NAD dependent deacetylases SIRT1 and SIRT2 in B-cell chronic lymphocytic leukemia (CLL). *Cancer Biol Ther*. (2016) 17:300–9. doi: 10.1080/15384047.2016.1139246
74. Waibel M, Christiansen AJ, Hibbs ML, Shortt J, Jones SA, Simpson I, et al. Manipulation of B-cell responses with histone deacetylase inhibitors. *Nat Commun*. (2015) 6:6838. doi: 10.1038/ncomms7838
75. Vachharajani VT, Liu T, Brown CM, Wang X, Buechler NL, Wells JD, et al. SIRT1 inhibition during the hypoinflammatory phenotype of sepsis enhances immunity and improves outcome. *J Leukoc Biol*. (2014) 96:785–96. doi: 10.1189/jlb.3MA0114-034RRR
76. Kumari S, Chaurasia SN, Nayak MK, Mallick RL, Dash D. Sirtuin inhibition induces apoptosis-like changes in platelets and thrombocytopenia. *J Biol Chem*. (2015) 290:12290–9. doi: 10.1074/jbc.M114.615948
77. Saini N, Yang X. Metformin as an anti-cancer agent: actions and mechanisms targeting cancer stem cells. *Acta Biochim Biophys Sin*. (2018) 50:133–43. doi: 10.1093/abbs/gmx106

78. Zhang W, Wu H, Yang M, Ye S, Li L, Zhang H, et al. SIRT1 inhibition impairs non-homologous end joining DNA damage repair by increasing Ku70 acetylation in chronic myeloid leukemia cells. *Oncotarget*. (2016) 7:13538–50. doi: 10.18632/oncotarget.6455
79. Zou T, Yang Y, Xia F, Huang A, Gao X, Fang D, et al. Resveratrol Inhibits CD4+ T cell activation by enhancing the expression and activity of Sirt1. *PLoS ONE*. (2013) 8:e75139. doi: 10.1371/journal.pone.0075139
80. Imler TJ Jr, Petro TM. Decreased severity of experimental autoimmune encephalomyelitis during resveratrol administration is associated with increased IL-17+IL-10+ T cells, CD4(-) IFN-gamma+ cells, and decreased macrophage IL-6 expression. *Int Immunopharmacol*. (2009) 9:134–43. doi: 10.1016/j.intimp.2008.10.015
81. Sanchez-Fidalgo S, Cardeno A, Villegas I, Talero E, de la Lastra CA. Dietary supplementation of resveratrol attenuates chronic colonic inflammation in mice. *Eur J Pharmacol*. (2010) 633:78–84. doi: 10.1016/j.ejphar.2010.01.025
82. Xuzhu G, Komai-Koma M, Leung BP, Howe HS, McSharry C, McInnes IB, et al. Resveratrol modulates murine collagen-induced arthritis by inhibiting Th17 and B-cell function. *Ann Rheum Dis*. (2012) 71:129–35. doi: 10.1136/ard.2011.149831
83. Wang B, Sun J, Li L, Zheng J, Shi Y, Le G. Regulatory effects of resveratrol on glucose metabolism and T-lymphocyte subsets in the development of high-fat diet-induced obesity in C57BL/6 mice. *Food Funct*. (2014) 5:1452–63. doi: 10.1039/C3FO60714C
84. Welsh KJ, Zhao B, Buja LM, Brown RE. Sirt1-positive lymphocytes in acute cellular cardiac allograft rejection: contributor to pathogenesis and a therapeutic target. *ASAIO J*. (2016) 62:349–53. doi: 10.1097/MAT.0000000000000338
85. Ye Q, Zhang M, Wang Y, Fu S, Han S, Wang L, et al. Sirtinol regulates the balance of Th17/Treg to prevent allograft rejection. *Cell Biosci*. (2017) 7:55. doi: 10.1186/s13578-017-0182-2

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Warren and MacIver. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.